Modern Cancer Therapy: Cryoablation Meets Immune Checkpoint Blockade

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Feb 22

PMID 38384806

Authors

Qi Liu

Chunyang Zhang

Xuxin Chen

Zhihai Han

Affiliations

Soon will be listed here.

Abstract

Cryoablation, as a minimally invasive technology for the treatment of tumors, destroys target tumors with lethal low temperatures. It simultaneously releases a large number of tumor-specific antigens, pro-inflammatory cytokines, and nucleoproteins, known as "danger signals", activating the body's innate and adaptive immune responses. However, tumor cells can promote the inactivation of immune effector cells by reprogramming immune checkpoints, leading to the insufficiency of these antigens to induce an immune response capable of eradicating the tumor. Immune checkpoint blockers rejuvenate exhausted T cells by blocking immune checkpoints that induce programmed death of T cells, and are therefore considered a promising therapeutic strategy to enhance the immune effects of cryoablation. In this review, we provide a detailed explanation of the immunological mechanisms of cryoablation and articulate the theoretical basis and research progress of the treatment of cancer with cryoablation combined with immune checkpoint blockers. Preliminary data indicates that this combined treatment strategy exhibits good synergy and has been proven to be safe and effective.

Citing Articles

Long term survival following cryoablation with adjuvant Toripalimab for anorectal malignant melanoma: a case report.

Jiang X, Ji Z, Li P, Yuan F, Lei X, Yang Y Front Oncol. 2025; 15:1465645.

PMID: 39926280 PMC: 11802423. DOI: 10.3389/fonc.2025.1465645.

Early Effects of Bronchoscopic Cryotherapy in Metastatic Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Single-Center Prospective Study.

Vasiliauskas G, Zemaite E, Skrodeniene E, Poskiene L, Maziliauskiene G, Macionis A Diagnostics (Basel). 2025; 15(2.

PMID: 39857085 PMC: 11763732. DOI: 10.3390/diagnostics15020201.

Exploring New Frontiers in Cryoablation and Immunotherapy Synergy.

Rivera Rodriguez D, Mouli S Radiol Imaging Cancer. 2024; 6(6):e240384.

PMID: 39545830 PMC: 11615622. DOI: 10.1148/rycan.240384.

References

Morad G, Helmink B, Sharma P, Wargo J . Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021; 184(21):5309-5337. PMC: 8767569. DOI: 10.1016/j.cell.2021.09.020. View

Liu Y, Sun Z . Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021; 11(11):5365-5386. PMC: 8039952. DOI: 10.7150/thno.58390. View

Park Y, Kuen D, Chung Y . Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med. 2018; 50(8):1-13. PMC: 6105674. DOI: 10.1038/s12276-018-0130-1. View

Derstine L, Soule E, Shabandi N, Arutyunova Z, Lall C, Scuderi C . Rare Treatment for a Rare Tumor: Cryoablation of a Granular Cell Tumor. Gastrointest Tumors. 2020; 7(1-2):41-49. PMC: 7206587. DOI: 10.1159/000504134. View

Kaiser M, Semeraro M, Herrmann M, Absenger G, Gerger A, Renner W . Immune Aging and Immunotherapy in Cancer. Int J Mol Sci. 2021; 22(13). PMC: 8269421. DOI: 10.3390/ijms22137016. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Mahoney J, Rosen A . Apoptosis and autoimmunity. Curr Opin Immunol. 2005; 17(6):583-8. DOI: 10.1016/j.coi.2005.09.018. View

Powles T, van der Heijden M, Castellano D, Galsky M, Loriot Y, Petrylak D . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020; 21(12):1574-1588. DOI: 10.1016/S1470-2045(20)30541-6. View

Gambichler T, Schroter U, Hoxtermann S, Susok L, Stockfleth E, Becker J . A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab. J Immunother. 2019; 42(7):265-268. DOI: 10.1097/CJI.0000000000000277. View

10.

Hashimoto M, Kamphorst A, Im S, Kissick H, Pillai R, Ramalingam S . CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annu Rev Med. 2018; 69:301-318. DOI: 10.1146/annurev-med-012017-043208. View

11.

Scandiffio R, Bozzi E, Ezeldin M, Capanna R, Ceccoli M, Colangeli S . Image-guided Cryotherapy for Musculoskeletal Tumors. Curr Med Imaging. 2020; 17(2):166-178. DOI: 10.2174/1573405616666200825162712. View

12.

Den Brok M, Sutmuller R, van der Voort R, Bennink E, Figdor C, Ruers T . In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004; 64(11):4024-9. DOI: 10.1158/0008-5472.CAN-03-3949. View

13.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

14.

Holmes D, Iyengar G . Breast Cancer Cryoablation in the Multidisciplinary Setting: Practical Guidelines for Patients and Physicians. Life (Basel). 2023; 13(8). PMC: 10456083. DOI: 10.3390/life13081756. View

15.

Shao Q, OFlanagan S, Lam T, Roy P, Pelaez F, Burbach B . Engineering T cell response to cancer antigens by choice of focal therapeutic conditions. Int J Hyperthermia. 2019; 36(1):130-138. DOI: 10.1080/02656736.2018.1539253. View

16.

Lopez-Soto A, Gonzalez S, Folgueras A . IFN Signaling and ICB Resistance: Time is on Tumor's Side. Trends Cancer. 2017; 3(3):161-163. DOI: 10.1016/j.trecan.2017.01.004. View

17.

Sabel M, Nehs M, Su G, Lowler K, Ferrara J, Chang A . Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat. 2005; 90(1):97-104. DOI: 10.1007/s10549-004-3289-1. View

18.

Barry K, Hsu J, Broz M, Cueto F, Binnewies M, Combes A . A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018; 24(8):1178-1191. PMC: 6475503. DOI: 10.1038/s41591-018-0085-8. View

19.

Schildberg F, Klein S, Freeman G, Sharpe A . Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016; 44(5):955-72. PMC: 4905708. DOI: 10.1016/j.immuni.2016.05.002. View

20.

Soerjomataram I, Bray F . Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070. Nat Rev Clin Oncol. 2021; 18(10):663-672. DOI: 10.1038/s41571-021-00514-z. View